Association of recipient variants with cGVHD in 10/10 HLA-matched siblings
| . | . | . | . | Discovery results . | Replication results . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variant* . | Gene . | Alleles† . | MAF‡ . | P . | HR§ . | LB . | UB . | Pǁ . | HR§ . | LB . | UB . |
| rs12559701 | NHS | C/T | 0.37 | 2.4E-07 | 0.70 | 0.6 | 0.8 | .005 | 0.79 | 0.7 | 0.9 |
| rs12558116 | NHS | T/C | 0.37 | 4.2E-07 | 0.71 | 0.6 | 0.8 | .005 | 0.79 | 0.7 | 0.9 |
| rs7057951 | NHS | C/A | 0.36 | 3.6E-07 | 0.70 | 0.6 | 0.8 | .011 | 0.81 | 0.7 | 1.0 |
| rs17246484 | NHS | T/C | 0.36 | 4.7E-07 | 0.71 | 0.6 | 0.8 | .007 | 0.80 | 0.7 | 0.9 |
| rs12007131 | NHS | T/C | 0.37 | 3.8E-07 | 0.70 | 0.6 | 0.8 | .006 | 0.80 | 0.7 | 0.9 |
| . | . | . | . | Discovery results . | Replication results . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Variant* . | Gene . | Alleles† . | MAF‡ . | P . | HR§ . | LB . | UB . | Pǁ . | HR§ . | LB . | UB . |
| rs12559701 | NHS | C/T | 0.37 | 2.4E-07 | 0.70 | 0.6 | 0.8 | .005 | 0.79 | 0.7 | 0.9 |
| rs12558116 | NHS | T/C | 0.37 | 4.2E-07 | 0.71 | 0.6 | 0.8 | .005 | 0.79 | 0.7 | 0.9 |
| rs7057951 | NHS | C/A | 0.36 | 3.6E-07 | 0.70 | 0.6 | 0.8 | .011 | 0.81 | 0.7 | 1.0 |
| rs17246484 | NHS | T/C | 0.36 | 4.7E-07 | 0.71 | 0.6 | 0.8 | .007 | 0.80 | 0.7 | 0.9 |
| rs12007131 | NHS | T/C | 0.37 | 3.8E-07 | 0.70 | 0.6 | 0.8 | .006 | 0.80 | 0.7 | 0.9 |
HR, hazard ratio; LB, lower boundary of the 95% confidence interval; MAF, minor allele frequency; SNP, single nucleotide polymorphism; UB, upper boundary of the 95% confidence interval.
All variants are in strong linkage disequilibrium with r2 > 0.90.
Plus strand major/minor alleles.
MAFs in the samples used for the test.
HRs reflect the allelic model.
The Bonferroni-corrected threshold of statistical significance is 0.025 based on the number of signals.